185 related articles for article (PubMed ID: 12916866)
1. Intermediate dose thalidomide (200 mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma.
Wechalekar AD; Chen CI; Sutton D; Reece D; Voralia M; Stewart AK
Leuk Lymphoma; 2003 Jul; 44(7):1147-9. PubMed ID: 12916866
[TBL] [Abstract][Full Text] [Related]
2. Low dose thalidomide in patients with relapsed or refractory multiple myeloma.
Kees M; Dimou G; Sillaber C; Drach J; Ackermann J; Lechner K; Gisslinger H
Leuk Lymphoma; 2003 Nov; 44(11):1943-6. PubMed ID: 14738147
[TBL] [Abstract][Full Text] [Related]
3. Low-dose thalidomide for multiple myeloma: interim analysis of a compassionate use program.
Steurer M; Spizzo G; Mitterer M; Gastl G
Onkologie; 2004 Apr; 27(2):150-4. PubMed ID: 15138347
[TBL] [Abstract][Full Text] [Related]
4. Thalidomide in relapsed/refractory multiple myeloma: pivotal trials conducted outside the United States.
Dimopoulos MA; Anagnostopoulos A
Semin Hematol; 2003 Oct; 40(4 Suppl 4):8-16. PubMed ID: 15015891
[TBL] [Abstract][Full Text] [Related]
5. Thalidomide in refractory and relapsing multiple myeloma.
Bladé J; Esteve J; Rosiñol L; Perales M; Montoto S; Tuset M; Montserrat E
Semin Oncol; 2001 Dec; 28(6):588-92. PubMed ID: 11740814
[TBL] [Abstract][Full Text] [Related]
6. The efficacy and tolerability of pomalidomide in relapsed/refractory myeloma patients in a "real-world" study: the Royal Marsden Hospital experience.
Sriskandarajah P; Pawlyn C; Mohammed K; Dearden CE; Davies FE; Morgan GJ; Boyd KD; Kaiser MF
Leuk Lymphoma; 2017 Feb; 58(2):494-497. PubMed ID: 27439571
[No Abstract] [Full Text] [Related]
7. Thalidomide dosing in patients with relapsed or refractory multiple myeloma.
Thompson JL; Hansen LA
Ann Pharmacother; 2003 Apr; 37(4):571-6. PubMed ID: 12659617
[TBL] [Abstract][Full Text] [Related]
8. Therapy with thalidomide in refractory multiple myeloma patients - the revival of an old drug.
Kneller A; Raanani P; Hardan I; Avigdor A; Levi I; Berkowicz M; Ben-Bassat I
Br J Haematol; 2000 Feb; 108(2):391-3. PubMed ID: 10691870
[TBL] [Abstract][Full Text] [Related]
9. Low incidence of thromboembolism in relapsed/refractory myeloma patients treated with thalidomide without thromboprophylaxis in Taiwan.
Wu SY; Yeh YM; Chen YP; Su WC; Chen TY
Ann Hematol; 2012 Nov; 91(11):1773-8. PubMed ID: 22706703
[TBL] [Abstract][Full Text] [Related]
10. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma.
Juliusson G; Celsing F; Turesson I; Lenhoff S; Adriansson M; Malm C
Br J Haematol; 2000 Apr; 109(1):89-96. PubMed ID: 10848786
[TBL] [Abstract][Full Text] [Related]
11. Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study.
Hou J; Jin J; Xu Y; Wu D; Ke X; Zhou D; Lu J; Du X; Chen X; Li J; Liu J; Gupta N; Hanley MJ; Li H; Hua Z; Wang B; Zhang X; Wang H; van de Velde H; Richardson PG; Moreau P
J Hematol Oncol; 2017 Jul; 10(1):137. PubMed ID: 28683766
[TBL] [Abstract][Full Text] [Related]
12. Clarithromycin with low dose dexamethasone and thalidomide is effective therapy in relapsed/refractory myeloma.
Morris TC; Kettle PJ; Drake M; Jones FC; Hull DR; Boyd K; Morrison A; Clarke P; O'Reilly P; Quinn J
Br J Haematol; 2008 Nov; 143(3):349-54. PubMed ID: 18759764
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas.
Fine HA; Figg WD; Jaeckle K; Wen PY; Kyritsis AP; Loeffler JS; Levin VA; Black PM; Kaplan R; Pluda JM; Yung WK
J Clin Oncol; 2000 Feb; 18(4):708-15. PubMed ID: 10673511
[TBL] [Abstract][Full Text] [Related]
14. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma.
Weber D; Rankin K; Gavino M; Delasalle K; Alexanian R
J Clin Oncol; 2003 Jan; 21(1):16-9. PubMed ID: 12506164
[TBL] [Abstract][Full Text] [Related]
15. Thalidomide for previously untreated indolent or smoldering multiple myeloma.
Rajkumar SV; Dispenzieri A; Fonseca R; Lacy MQ; Geyer S; Lust JA; Kyle RA; Greipp PR; Gertz MA; Witzig TE
Leukemia; 2001 Aug; 15(8):1274-6. PubMed ID: 11480571
[TBL] [Abstract][Full Text] [Related]
16. Thalidomide in low doses is effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukaemia.
Johnston RE; Abdalla SH
Leuk Lymphoma; 2002 Feb; 43(2):351-4. PubMed ID: 11999568
[TBL] [Abstract][Full Text] [Related]
17. Thalidomide in multiple myeloma.
Rajkumar SV
Oncology (Williston Park); 2000 Dec; 14(12 Suppl 13):11-6. PubMed ID: 11204667
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic dilemmas with thalidomide in multiple myeloma: case discussions.
Desikan RK; Jagannath S
Semin Oncol; 2001 Dec; 28(6):593-6. PubMed ID: 11740815
[TBL] [Abstract][Full Text] [Related]
19. The future role of thalidomide in multiple myeloma.
Boccadoro M; Blade J; Attal M; Palumbo A
Acta Haematol; 2005; 114 Suppl 1():18-22. PubMed ID: 16166768
[TBL] [Abstract][Full Text] [Related]
20. Thalidomide treatment of resistant or relapsed multiple myeloma patients.
Hus M; Dmoszynska A; Soroka-Wojtaszko M; Jawniak D; Legiec W; Ciepnuch H; Hellmann A; Wolska-Smolen T; Skotnicki A; Manko J;
Haematologica; 2001 Apr; 86(4):404-8. PubMed ID: 11325647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
